J
Joel Shapiro
Researcher at Erasmus University Rotterdam
Publications - 41
Citations - 3253
Joel Shapiro is an academic researcher from Erasmus University Rotterdam. The author has contributed to research in topics: Chemoradiotherapy & Neoadjuvant therapy. The author has an hindex of 22, co-authored 37 publications receiving 2559 citations. Previous affiliations of Joel Shapiro include Rochester General Health System & Utrecht University.
Papers
More filters
Journal ArticleDOI
Encoding of whisker input by cerebellar Purkinje cells
Laurens W. J. Bosman,Sebastiaan K. E. Koekkoek,Joel Shapiro,B. F. M. Rijken,Froukje Zandstra,Barry Van Der Ende,Cullen B. Owens,Jan-Willem Potters,Jornt R. De Gruijl,Jornt R. De Gruijl,Tom J. H. Ruigrok,Chris I. De Zeeuw,Chris I. De Zeeuw +12 more
TL;DR: It is described that individual Purkinje cells, at least under anaesthesia, may be bound in two functional ensembles based on the receptive fields and the synchrony of the complex spike and simple spike responses.
Journal ArticleDOI
Sarcopenia/Muscle Mass is not a Prognostic Factor for Short- and Long-Term Outcome After Esophagectomy for Cancer.
Brechtje A. Grotenhuis,Joel Shapiro,Stefan van Adrichem,Marianne de Vries,Marcel Koek,Bas P. L. Wijnhoven,J. Jan B. van Lanschot +6 more
TL;DR: The presence of sarcopenia was not associated with a negative short- and long-term outcome in this selected group of esophageal cancer patients after neoadjuvant chemoradiotherapy followed by esophagectomy.
Journal ArticleDOI
Three-gene immunohistochemical panel adds to clinical staging algorithms to predict prognosis for patients with esophageal adenocarcinoma.
Chin-Ann Johnny Ong,Joel Shapiro,Katie S. Nason,Jon M. Davison,Xinxue Liu,Caryn S. Ross-Innes,Maria O'Donovan,Winand N.M. Dinjens,Katharina Biermann,Nicholas B. Shannon,Susannah Bourne Worster,Laura Schulz,James D. Luketich,Bas P. L. Wijnhoven,Richard H. Hardwick,Rebecca C. Fitzgerald +15 more
TL;DR: A clinically applicable IHC biomarker panel, consisting of EGFR, TRIM44, and SIRT2, that is independently associated with OS and provides additional prognostic information to current survival predictors such as stage is identified and validated.
Journal ArticleDOI
Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol
Bo Jan Noordman,Joel Shapiro,Manon C.W. Spaander,Kausilia K. Krishnadath,Hanneke W. M. van Laarhoven,Mark I. van Berge Henegouwen,Grard A. P. Nieuwenhuijzen,Richard van Hillegersberg,Meindert N. Sosef,Ewout W. Steyerberg,Bas P. L. Wijnhoven,J. Jan B. van Lanschot +11 more
TL;DR: If this preSANO trial shows that the presence or absence of residual tumor can be predicted reliably 6 or 12 weeks after completion of n CRT, a randomized trial comparing nCRT plus standard surgery versus chemoradiotherapy plus “surgery as needed” will be conducted (SanO trial).
Journal ArticleDOI
Prolonged time to surgery after neoadjuvant chemoradiotherapy increases histopathological response without affecting survival in patients with esophageal or junctional cancer.
Joel Shapiro,Pieter van Hagen,Hester F. Lingsma,Bas P. L. Wijnhoven,Katharina Biermann,Fiebo J.W. ten Kate,Ewout W. Steyerberg,Ate van der Gaast,J. Jan B. van Lanschot +8 more
TL;DR: It is concluded that TTS can be safely prolonged from the usual 4 to 6 weeks up to at least 12 weeks, which facilitates a more conservative wait-and-see strategy after neoadjuvant chemoradiotherapy to be tested.